Deals Of The Week: AstraZeneca/Ardelyx, Roche/Inception, GlaxoSmithKline/Aeras
Vaxxas thinks its vaccine-enhancement technology platform, Nanopatch, can bring in milestones and royalties just like a biotech drug candidate by offering increased potency and easier administration to makers of vaccines.
You may also be interested in...
Unwinding NHE3 partnership with AstraZeneca, Ardelyx plans to move first-in-class agent into Phase III in IBS-C while seeking more tolerable dosing regimen for late-stage development in hyperphosphatasia.
MedImmune and two non-profit research organizations are collaborating on clinical trials that explore the tricky world of combinations of novel cancer immunotherapies, including three MedImmune compounds in different stages of development.
The newly formed Inception 3 will work to bring small molecule candidates for hearing loss, based on technology licensed from Stanford University, to IND-filing stage, at which point Roche will have the option to buy out the program.